EASY trial data indicate that angioplasty plus stenting via the radial artery can be done as a day procedure

Data from the EASY trial, an open-label, randomized study with 1,005 patients, suggest that angioplasty plus stenting of the coronary arteries via the radial artery can be safely done as a day procedure with one bolus dose of an antiplatelet drug as an anticoagulant, according to a presentation at the American Heart Association’s Scientific Sessions 2005.

“We propose a practice with more comfort for the patients, less risk of complications and greater cost-savings due to shorter hospitalizations,” said Olivier Bertrand, MD, PhD, assistant professor, faculty of medicine, Laval University in Quebec City, Canada, and interventional cardiologist at Laval Hospital.

The EArly Discharge after Trans-radial Stenting of CoronarY arteries (EASY) trial was designed to compare two treatments, one dose (a bolus) of an antiplatelet drug to reduce risk of blood clots with patient discharge 4 ? 6 hours later, and an initial dose followed by a 12-hour intravenous drip, with discharge the following morning.

In addition, 343 patients had predefined complications after angioplasty and received 12-hour infusions and hospitalization, as required. The group that received the single bolus was discharged the same day and had comparable outcomes after 40 days as those who got the infusion, Bertrand said.

The drug that was used in the study is abciximab, one of a class called the platelet glycoprotein IIb-IIIa receptor inhibitors.

The 30-day primary composite end-points included death, myocardial infarction, urgent revascularization, repeat hospitalization, major bleeding, access site complications, and severe thrombopenia.

The rate of events after adjustment for patients moved from the single-dose to the bolus-plus-infusion group was 13.5 percent in the single-dose group and 10.2 percent in the other group. As expected, the difference between the two randomized groups was small and statistically non-significant.

The results held up at six months and the researchers are continuing to follow the patients, Bertrand added.

 

 




DOLについて - 利用規約 -  会員規約 -  著作権 - サイトポリシー - 免責条項 - お問い合わせ
Copyright 2000-2025 by HESCO International, Ltd.